Dashboard
Manage Tickers

ALT Altimmune, Inc.

Nasdaq altimmune.com


$ 3.99 $ 0.00 (0 %)    

Wednesday, 15-Oct-2025 07:05:40 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 602.99 $ 0.00 (0 %)
DIA $ 465.13 $ 0.00 (0 %)
SPY $ 666.53 $ 0.00 (0 %)
TLT $ 90.99 $ 0.00 (0 %)
GLD $ 386.77 $ 0.00 (0 %)
$ 3.97
$ 3.92
$ 3.98 x 2
$ 4.01 x 435
-- - --
$ 2.90 - $ 11.16
2,010,525
na
350.38M
$ 1.12
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 02-27-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 03-27-2024 12-31-2023 10-K
8 11-07-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 02-28-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-11-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-15-2022 12-31-2021 10-K
16 11-09-2021 09-30-2021 10-Q
17 08-10-2021 06-30-2021 10-Q
18 05-17-2021 03-31-2021 10-Q
19 02-25-2021 12-31-2020 10-K
20 11-09-2020 09-30-2020 10-Q
21 08-11-2020 06-30-2020 10-Q
22 05-13-2020 03-31-2020 10-Q
23 03-27-2020 12-31-2019 10-K
24 11-13-2019 09-30-2019 10-Q
25 08-13-2019 06-30-2019 10-Q
26 05-14-2019 03-31-2019 10-Q
27 04-01-2019 12-31-2018 10-K
28 11-13-2018 09-30-2018 10-Q
29 08-14-2018 06-30-2018 10-Q
30 05-15-2018 03-31-2018 10-Q
31 04-02-2018 12-31-2017 10-K
32 11-09-2017 09-30-2017 10-Q
33 08-14-2017 06-30-2017 10-Q
34 05-03-2017 03-31-2017 10-Q
35 03-14-2017 12-31-2016 10-K
36 11-04-2016 09-30-2016 10-Q
37 08-04-2016 06-30-2016 10-Q
38 05-09-2016 03-31-2016 10-Q
39 03-11-2016 12-31-2015 10-K
40 11-06-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

altimmune-stock-a-deep-dive-into-analyst-perspectives-4-ratings
Altimmune Stock: A Deep Dive Into Analyst ...
10/10/2025 12:02:09

hc-wainwright--co-reiterates-buy-on-altimmune-maintains-12-price-target
HC Wainwright & Co. Reiterates Buy on Alti...
10/10/2025 11:04:27

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Altimmune (NASDAQ:ALT) with a Buy and maintains $12 price tar...

Core News & Articles
10 Health Care Stocks With Whale Alerts In...
09/29/2025 17:35:29

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and...

radian-group-intel-nanobiotix-crowdstrike-and-other-big-stocks-moving-higher-on-thursday
Radian Group, Intel, Nanobiotix, CrowdStri...
09/18/2025 14:19:12

altimmune-announces-pemvidutide-as-the-only-drug-granted-fast-track-designation-in-alcohol-use-disorder-with-phase-2-reclaim-study-ongoing
Altimmune Announces Pemvidutide As The Onl...
08/19/2025 11:33:43

Pemvidutide is the only drug currently granted Fast Track Designation in AUDRECLAIM, a Phase 2 trial of pemvidutide in AUD, is ...

what-5-analyst-ratings-have-to-say-about-altimmune
What 5 Analyst Ratings Have To Say About A...
08/13/2025 21:01:18

these-analysts-slash-their-forecasts-on-altimmune-following-q2-results
These Analysts Slash Their Forecasts On Al...
08/13/2025 18:57:23

hc-wainwright--co-reiterates-buy-on-altimmune-maintains-12-price-target
HC Wainwright & Co. Reiterates Buy on Alti...
08/13/2025 17:49:53

HC Wainwright & Co. analyst Patrick Trucchio reiterates Altimmune (NASDAQ:ALT) with a Buy and maintains $12 price target.

ubs-maintains-buy-on-altimmune-lowers-price-target-to-24
UBS Maintains Buy on Altimmune, Lowers Pri...
08/13/2025 15:51:40

UBS analyst Eliana Merle maintains Altimmune (NASDAQ:ALT) with a Buy and lowers the price target from $26 to $24.

b-riley-securities-maintains-buy-on-altimmune-lowers-price-target-to-18
B. Riley Securities Maintains Buy on Altim...
08/13/2025 12:34:39

B. Riley Securities analyst Mayank Mamtani maintains Altimmune (NASDAQ:ALT) with a Buy and lowers the price target from $20 ...

altimmune-q2-fy2025-earnings-call-transcript
Altimmune Q2 FY2025 Earnings Call Transcript
08/12/2025 14:18:39

Altimmune Q2 FY2025 earnings call transcript

altimmune-q2-eps-027-beats-032-estimate-sales-5000k-beat-560000-estimate
Altimmune Q2 EPS $(0.27) Beats $(0.32) Est...
08/12/2025 11:03:11

Core News & Articles
Earnings Scheduled For August 12, 2025
08/12/2025 08:32:28

uncovering-potential-altimmunes-earnings-preview
Uncovering Potential: Altimmune's Earnings...
08/11/2025 18:02:56

altimmune-names-jerry-durso-chairman-as-company-prepares-for-phase-3-development-of-pemvidutide-in-mash
Altimmune Names Jerry Durso Chairman As Co...
08/11/2025 11:37:48

Appointment recognizes Mr. Durso's extensive commercial expertise as Altimmune prepares for Phase 3 development of pemvidut...

jmp-securities-maintains-market-outperform-on-altimmune-lowers-price-target-to-15
JMP Securities Maintains Market Outperform...
07/10/2025 13:24:05

JMP Securities analyst Jonathan Wolleben maintains Altimmune (NASDAQ:ALT) with a Market Outperform and lowers the price targ...

methode-electronics-ultragenyx-pharmaceutical-and-other-big-stocks-moving-lower-in-thursdays-pre-market-session
Methode Electronics, Ultragenyx Pharmaceut...
07/10/2025 12:00:22

altimmune-initiates-restore-phase-2-trial-evaluating-efficacy-and-safety-of-pemvidutide-for-alcohol-associated-liver-disease
Altimmune Initiates RESTORE Phase 2 Trial ...
07/09/2025 11:33:00

altimmune-enrols-first-patient-in-restore-phase-2-trial-evaluating-efficacy-and-safety-of-pemvidutide-in-subjects-with-alcohol-associated-liver-disease
Altimmune Enrols First Patient In RESTORE ...
07/09/2025 11:31:31

Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for l...

benzinga-bulls-and-bears-nvidia-micron-hims--and-markets-soar-on-mideast-and-tariff-relief
Benzinga Bulls And Bears: Nvidia, Micron, ...
06/28/2025 12:00:31

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our t...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION